Rezumat TESLOIANU ANDA - Gr.T. Popa

24. Mukerjee D, St George D, Knight C, et al. Echocardio graph y and
pulmonary fun ction as screenin g tests fo r pulmonary arterial h yperten sion
in systemic sclerosis. Rheumatology 2004; 43: 461 –466.
25. Launay D, Mouthon L, Hachulla E, et al. Prevalence and ch aracteristics
of moderate to severe pulmonary h yperten sion in systemic sclerosis with
and without interstitial lu ng disease. J Rheu matol 2 007; 34: 1005 –1011.
26. Torbicki A Cardiac magnetic resonan ce in pulmo nary arterial
h yperten sion, a step in the right direction. Eu r Heart J 2007; 28: 1187 –
1189.
27. Rich S, Kieras K, Gro ves B, et al . Antinu clear antibodies in primary
pulmonary h yperten sion. J Am Coll Cardiol 1986; 8: 1307 –1311.
28. Chu JW, Kao PN, Faul JL, et al. High prevalen ce of autoimmun e
th yroid disease in pulmonary arterial h yp erten sion. Chest 2002; 122: 1668 –
1673.
29. Naeije R. Hep atopulmonary syndro me and portopulmonary
h yperten sion. Swiss Med Wkly 2003; 133: 163 –169.
30. Hoeper MM, Lee SH, Voswinckel R, et al. Co mplications o f right heart
cath eterization procedures in patients with pulmon ary h yp erten sion in
exp erienced centers. J Am Coll Cardiol 2006; 48: 25 46 –2552.
31.Ross RM. ATS/ACCP statement on cardiopulmonary exercise testin g.
Am J Respir Crit Care Med 2003; 167: 1451.
32. Palange P, Ward SA, Carlsen KH, et al. Reco mmend ations on th e use o f
exercise testin g in clinical practice. Eu r Respir J 20 07; 29: 185 –209.
33. Voelkel MA, Wynn e KM, Bad esch DB, et al. Hyperuricemia in severe
pulmonary h yperten sion. Chest 2000; 117: 19 –24.
34. McLau ghlin VV, McGoon MD. Pulmonary arterial h yp ertension.
Circulation 2006; 114: 1417 –1431.
35. Sitbon O, McLau ghlin VV, Badesch DB, et al. Su rvival in p atients with
class III idiopathic pulmo nary arterial h yp ertension treated with first lin e
oral bosentan co mp ared with an historical cohort o f patients started on
intravenous epopro stenol. Thorax 2005; 60: 1025 –1030.
36. Sun XG, Hansen JE, Oudiz R, et al. Exercise p athophysiolo gy in
patients with primary pulmonary h yperten sion. Circulation 2001; 104: 429 –
435.
37. McLau ghlin VV, Shillington A, Rich S. Survival in primary pulmon ary
h yperten sion: the imp act of epoprostenol th erap y. Circulation 2002; 106:
1477–1482.
32